AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9316009 — intervention group
Group type: COMPARATOR
Intervention: Oral etoposide 50 mg/m2 on days 1-21 alone (Group II)
Number of subjects: 120
Study 9316009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carboplatin (CBDCA) with etoposide (Group I)
Number of subjects: 120
Study 9316009 — intervention group
Group type: COMPARATOR
Intervention: Oral etoposide alone (Group II)
Number of subjects: 120
Study 8403797 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran supplementation
Number of subjects: 67
Study 8403797 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran supplementation
Number of subjects: 67
Study 8403797 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 67
Study 3875515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetacaine spray
Number of subjects: 0
Study 3875515 — intervention group
Group type: EXPERIMENTAL
Intervention: Hurricaine spray
Number of subjects: 0
Study 3875515 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Xylocaine spray
Number of subjects: 0
Study 3875515 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gargle
Number of subjects: 0
Study 3875515 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine diluted 1:1 with mouthwash gargle
Number of subjects: 0
Study 3875515 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine diluted 1:1 with another mouthwash gargle
Number of subjects: 0
Study 31897528 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate
Number of subjects: 2000
Study 31897528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 29971997 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular intradermal needling combined with erjian (HX6,7i) bloodletting
Number of subjects: 90
Study 29971997 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of estazolam (1mg each day for 4 weeks)
Number of subjects: 90
Study 29971997 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 27134062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention study
Number of subjects: 70
Study 24070810 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial tears (ATs)
Number of subjects: 18
Study 24070810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold compress (CC)
Number of subjects: 18
Study 24070810 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial tears combined with cold compress (ATs + CC)
Number of subjects: 18
Study 24070810 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine hydrochloride (EH)
Number of subjects: 18
Study 24070810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold compress combined with artificial tears (CC + ATs)
Number of subjects: 18
Study 24070810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold compress combined with epinastine hydrochloride (CC + EH)
Number of subjects: 18
Study 24070810 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial tears alone (ATs)
Number of subjects: 18
Study 24070810 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine hydrochloride combined with cold compress (EH + CC)
Number of subjects: 18
Study 24070810 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study 22975501 — intervention group
Group type: EXPERIMENTAL
Intervention: OHA 2 mg, 4 mg, and 8 mg (single and multiple doses)
Number of subjects: 42
Study 22975501 — intervention group
Group type: COMPARATOR
Intervention: OHA 4 mg (fed condition)
Number of subjects: 42
Study 22975501 — intervention group
Group type: EXPERIMENTAL
Intervention: OHA (single-dose and multiple-dose) in elderly
Number of subjects: 42
Study 20937148 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-Linked Care (TLC) Diabetes program
Number of subjects: 340
Study 20937148 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 340
Study 19385465 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed technique (Group A)
Number of subjects: 70
Study 19385465 — intervention group
Group type: COMPARATOR
Intervention: Open technique (Group B)
Number of subjects: 70
Study 15951089 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 100 mg/day
Number of subjects: 38
Study 15951089 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 300 mg/day
Number of subjects: 38
Study 15951089 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 600 mg/day
Number of subjects: 38
Study 15951089 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine with plasma levels > 150 ng/ml
Number of subjects: 38
Study 15951089 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine regardless of dose
Number of subjects: 38
Study 15951089 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine at the end of the last trial
Number of subjects: 38
Study 12663361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice cooling jacket before and during exercise
Number of subjects: 7
Study 12663361 — intervention group
Group type: COMPARATOR
Intervention: Control (no cooling jacket)
Number of subjects: 7
Study 10066007 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose clomipramine
Number of subjects: 180
Study 10066007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose clomipramine
Number of subjects: 180
Study 10066007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 8933676 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb AS
Number of subjects: 30
Study 8933676 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb AC
Number of subjects: 30
Study 8933676 — intervention group
Group type: COMPARATOR
Intervention: Hb AA
Number of subjects: 30
Study 2053092 — intervention group
Group type: EXPERIMENTAL
Intervention: Group meetings with families (4 to 40 at a time)
Number of subjects: 0
Study 2053092 — intervention group
Group type: EXPERIMENTAL
Intervention: Open communication with families by highly qualified physicians
Number of subjects: 0
Study 6151492 — intervention group
Group type: EXPERIMENTAL
Intervention: Indalpine
Number of subjects: 35
Study 6151492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 30879774 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler flowmetry
Number of subjects: 74
Study 30879774 — intervention group
Group type: COMPARATOR
Intervention: Electric pulp test
Number of subjects: 74
Study 30879774 — intervention group
Group type: COMPARATOR
Intervention: Ethyl chloride
Number of subjects: 74
Study 30416635 — intervention group
Group type: COMPARATOR
Intervention: Epidural Block
Number of subjects: 80
Study 30416635 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse Abdominis Plane (TAP) Block
Number of subjects: 80
Study 26946731 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog days plaster (acupoint application)
Number of subjects: 249
Study 26946731 — intervention group
Group type: COMPARATOR
Intervention: Placebo (buckwheat plaster without medical ingredient)
Number of subjects: 249
Study 24969712 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 35
Study 24969712 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy with HFCWO
Number of subjects: 35
Study 22268427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional 1,550-nm Yb/Er fiber laser
Number of subjects: 22
Study 22268427 — intervention group
Group type: COMPARATOR
Intervention: Variable square pulse 2,940-nm Er:YAG laser
Number of subjects: 22
Study 22268427 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 22
Study 19702465 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease (PD) group
Number of subjects: 52
Study 19702465 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 52
Study 19702465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PD and healthy controls)
Number of subjects: 52
Study 19702465 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor symptom severity in PD patients
Number of subjects: 52
Study 17405901 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus bevacizumab (10 mg/kg, i.v. infusion on day 1, every 2 weeks)
Number of subjects: 829
Study 17405901 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus bevacizumab
Number of subjects: 829
Study 17405901 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 alone
Number of subjects: 829
Study 16762801 — intervention group
Group type: EXPERIMENTAL
Intervention: Big endothelin-1 (Big ET-1)
Number of subjects: 2359
Study 12486422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cpn IgA > or =1:32
Number of subjects: 178
Study 12486422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cpn IgA > or =1:16
Number of subjects: 178
Study 12486422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cpn IgA > or =1:64
Number of subjects: 178
Study 12486422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cpn IgA > or =1:128
Number of subjects: 178
Study 12486422 — intervention group
Group type: COMPARATOR
Intervention: Cpn IgG
Number of subjects: 178
Study 10453433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (187 patients) with systematic lipid assessment and active pharmacologic lipid therapy.
Number of subjects: 238
Study 10453433 — intervention group
Group type: COMPARATOR
Intervention: Control group (51 patients) with no systematic lipid lowering intervention.
Number of subjects: 238
Study 8542224 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 20
Study 8542224 — intervention group
Group type: COMPARATOR
Intervention: No fibrin sealant
Number of subjects: 20
Study 2675597 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict diabetic protocol (diet and insulin therapy)
Number of subjects: 126
Study 2675597 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (baseline capillary blood glucose testing)
Number of subjects: 126
Study 2675597 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated group
Number of subjects: 126
Study 2675597 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal oral glucose tolerance test)
Number of subjects: 126
Study 322251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolvent tablets containing mixed enzyme preparations
Number of subjects: 100
Study 322251 — intervention group
Group type: COMPARATOR
Intervention: Dissolvent tablets containing pure enzymes
Number of subjects: 100
Study 322251 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 100
Study 322251 — intervention group
Group type: COMPARATOR
Intervention: Steradent tablets
Number of subjects: 100
Study 30105946 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based self-teaching course
Number of subjects: 165
Study 30105946 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led course
Number of subjects: 165
Study 29268061 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion
Number of subjects: 50
Study 29268061 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 50
Study 26356402 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 60
Study 23637967 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg CPG 7909 as adjuvant
Number of subjects: 68
Study 23637967 — intervention group
Group type: COMPARATOR
Intervention: Placebo-adjuvant
Number of subjects: 68
Study 21991704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled lignocaine gel (4 degrees C)
Number of subjects: 60
Study 21991704 — intervention group
Group type: COMPARATOR
Intervention: Room temperature lignocaine gel (20 degrees C)
Number of subjects: 60
Study 19189349 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete resection (group A)
Number of subjects: 3126
Study 19189349 — intervention group
Group type: COMPARATOR
Intervention: Small residual tumor burden of 1-10 mm (group B)
Number of subjects: 3126
Study 19189349 — intervention group
Group type: COMPARATOR
Intervention: Macroscopic residual disease exceeding 1 cm (group C)
Number of subjects: 3126
Study 16456657 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (12 microg/kg body weight)
Number of subjects: 33
Study 16456657 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 33
Study 14683737 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 2180
Study 16750781 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-dependent vasodilation (EDV)
Number of subjects: 75
Study 16750781 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-independent vasodilation (EIV)
Number of subjects: 75
Study 16750781 — intervention group
Group type: EXPERIMENTAL
Intervention: EDV response of 8%
Number of subjects: 75
Study 10562823 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg base/kg body weight over 3 days) + Primaquine (15 mg daily for 14 days)
Number of subjects: 886
Study 10562823 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (25 mg base/kg body weight over 3 days)
Number of subjects: 886
Study 7575779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (cyA)
Number of subjects: 66
Study 7575779 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone and azathioprine
Number of subjects: 66
Study 1686131 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 0.5 mg/h
Number of subjects: 51
Study 1686131 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 0.1 mg/h
Number of subjects: 51
Study 1686131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7272160 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 7
Study 7272160 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol 80 mg
Number of subjects: 7
Study 31470806 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 10
Study 31470806 — intervention group
Group type: COMPARATOR
Intervention: Gastric distension
Number of subjects: 10
Study 30171752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal local anesthesia (IRLA)
Number of subjects: 253
Study 30171752 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block anesthesia (PPNB)
Number of subjects: 253
Study 30171752 — intervention group
Group type: COMPARATOR
Intervention: Control (blank)
Number of subjects: 253
Study 27249891 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-point SMBG
Number of subjects: 191
Study 27249891 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point SMBG
Number of subjects: 191
Study 27249891 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 191
Study 25295719 — intervention group
Group type: COMPARATOR
Intervention: PCIA with morphine (M group)
Number of subjects: 60
Study 25295719 — intervention group
Group type: COMPARATOR
Intervention: PCIA with tramadol (T group)
Number of subjects: 60
Study 25295719 — intervention group
Group type: COMPARATOR
Intervention: PCIA with tramadol combined with lornoxicam (L group)
Number of subjects: 60
Study 22777991 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous sulfate (80 mg of elemental iron daily)
Number of subjects: 198
Study 22777991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 20456306 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 262
Study 20456306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 17563739 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 2 (IL-2) at 1 million units/m² SQ daily for 28 days
Number of subjects: 72
Study 17563739 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) at 1.25 mg/kg intravenously daily from day 0 to +28 and interferon gamma (IFN-gamma) 0.025 mg/m² SQ every 2 days from day +7 to +28
Number of subjects: 72
Study 15712603 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine releasing test (HRT)
Number of subjects: 21
Study 15712603 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (INF)-gamma releasing test
Number of subjects: 21
Study 15712603 — intervention group
Group type: EXPERIMENTAL
Intervention: CellScan test (CST)
Number of subjects: 21
Study 15712603 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine releasing test (HRT) for high suspicion level drugs
Number of subjects: 21
Study 15712603 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (INF)-gamma releasing test for high suspicion level drugs
Number of subjects: 21
Study 15712603 — intervention group
Group type: EXPERIMENTAL
Intervention: CellScan method for high suspicion level drugs
Number of subjects: 21
Study 15712603 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine releasing test (HRT) for low suspicion level drugs
Number of subjects: 21
Study 15712603 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (INF)-gamma releasing test for low suspicion level drugs
Number of subjects: 21
Study 15712603 — intervention group
Group type: EXPERIMENTAL
Intervention: CellScan method for low suspicion level drugs
Number of subjects: 21
Study 15712603 — intervention group
Group type: COMPARATOR
Intervention: CellScan method (CST) in controls
Number of subjects: 21
Study 11870013 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline and interpersonal psychotherapy
Number of subjects: 49
Study 11870013 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline and clinic visits
Number of subjects: 49
Study 11870013 — intervention group
Group type: COMPARATOR
Intervention: Placebo and psychotherapy
Number of subjects: 49
Study 11870013 — intervention group
Group type: COMPARATOR
Intervention: Placebo and clinic visits
Number of subjects: 49
Study 10097871 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 0
Study 10097871 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative treatment options (including psychopharmacology)
Number of subjects: 0
Study 8668449 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised walking group
Number of subjects: 27
Study 8668449 — intervention group
Group type: COMPARATOR
Intervention: Nonwalking group
Number of subjects: 27
Study 2403654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (100 mg/kg/day, intravenously once daily; n = 53)
Number of subjects: 106
Study 2403654 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (240 mg/kg/day, intravenously in four equal doses; n = 53)
Number of subjects: 106
Study 2403654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 106
Study 2403654 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 106
Study 31143952 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol (2 × 180 s per vein)
Number of subjects: 70
Study 31143952 — intervention group
Group type: EXPERIMENTAL
Intervention: TTI-guided approach (TTI + 120 s per vein or 1 × 180 s if TTI could not be measured)
Number of subjects: 70
Study 29878691 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered self-management empowerment intervention (PCSMEI)
Number of subjects: 144
Study 29878691 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control Group)
Number of subjects: 144
Study 27080652 — intervention group
Group type: EXPERIMENTAL
Intervention: Deactivated indiscriminable electrodes for a minimum of 2 months
Number of subjects: 13
Study 27080652 — intervention group
Group type: EXPERIMENTAL
Intervention: Deactivated discriminable electrodes
Number of subjects: 13
Study 27080652 — intervention group
Group type: COMPARATOR
Intervention: Optimised clinical maps
Number of subjects: 13
Study 25442042 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with oxaliplatin (130 mg/m² on day 1) and capecitabine (1000 mg/m² twice daily for 14 days every 3 weeks), followed by chemoradiation therapy (50 Gy over 5 weeks with modified XELOX regimen), and then consolidation chemotherapy with XELOX regimen.
Number of subjects: 51
Study 25442042 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant sandwich treatment using XELOX regimen as induction, concomitant, and consolidation chemotherapy.
Number of subjects: 51
Study 22071420 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnCl2 2.5mM
Number of subjects: 9
Study 22071420 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnCl2 5mM
Number of subjects: 9
Study 22071420 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnCl2 10mM
Number of subjects: 9
Study 22071420 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnCl2 20mM
Number of subjects: 9
Study 22071420 — intervention group
Group type: COMPARATOR
Intervention: Control (Double Distilled Water)
Number of subjects: 9
Study 20651221 — intervention group
Group type: EXPERIMENTAL
Intervention: G0 (glucose ingested at onset of cold exposure)
Number of subjects: 0
Study 20651221 — intervention group
Group type: COMPARATOR
Intervention: G60 (glucose ingested after 60 min of cold exposure)
Number of subjects: 0
Study 19357442 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin, 10 mg, twice a day for 1 week
Number of subjects: 24
Study 19357442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15167462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold temperatures applied to enamel using tetrafluoroethane
Number of subjects: 18
Study 15167462 — intervention group
Group type: COMPARATOR
Intervention: Cold temperatures applied to enamel
Number of subjects: 18
Study 12068838 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid
Number of subjects: 11
Study 9839759 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl 1 mg
Number of subjects: 27
Study 9839759 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl 3 mg
Number of subjects: 27
Study 9839759 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl 5 mg
Number of subjects: 27
Study 9839759 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl (all doses)
Number of subjects: 27
Study 9839759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7806692 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone (10 mg capsules, thrice daily, up to 120 mg daily)
Number of subjects: 60
Study 7806692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2760597 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 0
Study 2760597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0